331 related articles for article (PubMed ID: 15647651)
41. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
Newton M; Burnham WR; Kamm MA
Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269
[TBL] [Abstract][Full Text] [Related]
42. Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study.
Hoogendoorn RJ; Groeneveld L; Kwee JA
Clin Drug Investig; 2009; 29(12):803-10. PubMed ID: 19888786
[TBL] [Abstract][Full Text] [Related]
43. [All proton pump inhibitors are equally efficacious in standard dosages].
Hellström PM; Vitols S
Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
[TBL] [Abstract][Full Text] [Related]
44. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Frazzoni M; De Micheli E; Grisendi A; Savarino V
Aliment Pharmacol Ther; 2003 Jan; 17(2):235-41. PubMed ID: 12534408
[TBL] [Abstract][Full Text] [Related]
45. Acid pump inhibitors. The treatment of gastroesophageal reflux.
Hetzel D
Aust Fam Physician; 1998 Jun; 27(6):487-91. PubMed ID: 9648315
[TBL] [Abstract][Full Text] [Related]
46. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Thomson AB
Curr Gastroenterol Rep; 2000 Dec; 2(6):482-93. PubMed ID: 11079051
[TBL] [Abstract][Full Text] [Related]
47. Early relief of upper gastrointestinal dyspeptic symptoms: a survey of empirical therapy with pantoprazole in Canadian clinical practice.
Armstrong D; Kazim F; Gervais M; Pyzyk M
Can J Gastroenterol; 2002 Jul; 16(7):439-50. PubMed ID: 12177723
[TBL] [Abstract][Full Text] [Related]
48. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms.
Scholten T; Gatz G; Hole U
Aliment Pharmacol Ther; 2003 Sep; 18(6):587-94. PubMed ID: 12969085
[TBL] [Abstract][Full Text] [Related]
49. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
Calabrese C; Liguori G; Gabusi V; Gionchetti P; Rizzello F; Straforini G; Brugnera R; Di Febo G
Aliment Pharmacol Ther; 2008 Jul; 28(2):250-5. PubMed ID: 18485128
[TBL] [Abstract][Full Text] [Related]
50. Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study.
Eherer AJ; Habermann W; Hammer HF; Kiesler K; Friedrich G; Krejs GJ
Scand J Gastroenterol; 2003 May; 38(5):462-7. PubMed ID: 12795454
[TBL] [Abstract][Full Text] [Related]
51. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
Robinson M
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():30-7. PubMed ID: 15496216
[TBL] [Abstract][Full Text] [Related]
52. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
53. Esomeprazole.
Spencer CM; Faulds D
Drugs; 2000 Aug; 60(2):321-9; discussion 330-1. PubMed ID: 10983736
[TBL] [Abstract][Full Text] [Related]
54. Clinical efficacy of pantoprazole compared with ranitidine.
Bader JP; Delchier JC
Aliment Pharmacol Ther; 1994; 8 Suppl 1():47-52. PubMed ID: 8180294
[TBL] [Abstract][Full Text] [Related]
55. Comparison of the efficacy and safety of pantoprazole magnesium and pantoprazole sodium in the treatment of gastro-oesophageal reflux disease: a randomized, double-blind, controlled, multicentre trial.
Hein J
Clin Drug Investig; 2011; 31(9):655-64. PubMed ID: 21819161
[TBL] [Abstract][Full Text] [Related]
56. Esomeprazole versus pantoprazole for healing erosive oesophagitis.
Vcev A; Begić I; Ostojić R; Jurcić D; Bozić D; Soldo I; Gmajnić R; Kondza G; Khaznadar E; Mićunović N
Coll Antropol; 2006 Sep; 30(3):519-22. PubMed ID: 17058517
[TBL] [Abstract][Full Text] [Related]
57. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
Diav-Citrin O; Arnon J; Shechtman S; Schaefer C; van Tonningen MR; Clementi M; De Santis M; Robert-Gnansia E; Valti E; Malm H; Ornoy A
Aliment Pharmacol Ther; 2005 Feb; 21(3):269-75. PubMed ID: 15691301
[TBL] [Abstract][Full Text] [Related]
58. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study.
Corinaldesi R; Valentini M; Belaïche J; Colin R; Geldof H; Maier C
Aliment Pharmacol Ther; 1995 Dec; 9(6):667-71. PubMed ID: 8824655
[TBL] [Abstract][Full Text] [Related]
59. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
60. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Eklund S;
Aliment Pharmacol Ther; 2005 Mar; 21(6):739-46. PubMed ID: 15771760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
